Cannabinoid Based Pharmaceutical Products
Cannabinoid based pharmaceutical product may help rare skin disease.
“My name is Eric Adams. I’m the president and CEO of InMed Pharmaceuticals in Vancouver B.C. InMed is a bio-pharmaceutical company that specializes in the research development and commercialization of cannabinoid based pharmaceutical products. We take this class of compounds known as cannabinoids and we formulate these into disease specific products to treat diseases with high unmet medical needs. We differentiate ourselves from our competitors in three particular ways. First of all, we don’t grow any marijuana. We bio synthesize these compounds in a laboratory setting and then use those in our formulations. Secondly, we don’t use any THC in our products. Our goal is to treat the disease, not to have any psychoactive side effects that may adversely affect the patient. And third, our products are applied topically to the sites of disease. We think this is important in order to minimize the amount of drug that’s needed and minimize the amount that is circulating throughout the body. Is one of the most devastating diseases that most people never heard of. Epidermolysis Bullosa or EB is one of the most devastating diseases that most people never heard of. Essentially the layers of the skin are not connected to each other and can be very easily bruised or torn, leading to open wounds that overtime can be deadly. In addition to the improvement of symptoms, we believe there may be the potential for INM-750 to bring some degree of disease modification in patients with a certain type of EB called EB Simplex. InMed is in advanced pre-clinical studies now to demonstrate the safety and efficacy prior to entering into human clinical trials. InMed is an innovative pharmaceutical company that uses the cutting edge technologies needed to design products and deliver those to patients with the utmost safety and efficacy. InMed is traded on the Toronto Stock Exchange under the symbol IN and on the OTCQX in the United States under the symbol IMLFF.” – Eric Adams, President and CEO of InMed Pharmaceuticals
For more information on InMed Pharmaceuticals (IN:TSX,IMLFF:OTCQX) please fill out the form below.